IMPEL PHARMACEUTICALS INC (IMPL) Stock Price, Forecast & Analysis
USA - NASDAQ:IMPL - US45258K1097 - Common Stock
IMPL Key Statistics, Chart & Performance
The current stock price of IMPL is 0.2411 USD. In the past month the price decreased by -32.08%. In the past year, price decreased by -93.3%.
IMPL Latest News, Press Relases and Analysis
IMPL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.59 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 350.8 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.77 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Related stock screener links
About IMPL
Company Profile
Impel Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 160 full-time employees. The company went IPO on 2021-04-23. The firm has designed its Precision Olfactory Delivery (POD) technology to target the vascular-rich upper nasal space, and to provide rapid absorption, consistent drug biodistribution and ease of use for a patient, provider, or caregiver. The Company’s product, Trudhesa, is a liquid formulation of dihydroergotamine (DHE), administered to the upper nasal space using its proprietary POD technology for the acute treatment of migraine headaches with or without aura in adults. The firm is developing its product candidate, INP105, as an upper nasal formulation of olanzapine administered using its POD technology for the treatment of agitation and aggression associated with autism spectrum disorder (ASD).
Company Info
IMPEL PHARMACEUTICALS INC
201 Elliott Ave. W, Suite 260
Seattle WASHINGTON US
CEO: Adrian Adams
Employees: 160
Phone: 12065681466
IMPEL PHARMACEUTICALS INC / IMPL FAQ
What does IMPL do?
Impel Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 160 full-time employees. The company went IPO on 2021-04-23. The firm has designed its Precision Olfactory Delivery (POD) technology to target the vascular-rich upper nasal space, and to provide rapid absorption, consistent drug biodistribution and ease of use for a patient, provider, or caregiver. The Company’s product, Trudhesa, is a liquid formulation of dihydroergotamine (DHE), administered to the upper nasal space using its proprietary POD technology for the acute treatment of migraine headaches with or without aura in adults. The firm is developing its product candidate, INP105, as an upper nasal formulation of olanzapine administered using its POD technology for the treatment of agitation and aggression associated with autism spectrum disorder (ASD).
Can you provide the latest stock price for IMPEL PHARMACEUTICALS INC?
The current stock price of IMPL is 0.2411 USD. The price decreased by -41.79% in the last trading session.
Does IMPEL PHARMACEUTICALS INC pay dividends?
IMPL does not pay a dividend.
What is the ChartMill technical and fundamental rating of IMPL stock?
IMPL has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists IMPL stock?
IMPL stock is listed on the Nasdaq exchange.
Would investing in IMPEL PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IMPL.
IMPL Technical Analysis
IMPL Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to IMPL. Both the profitability and financial health of IMPL have multiple concerns.
IMPL Financial Highlights
Over the last trailing twelve months IMPL reported a non-GAAP Earnings per Share(EPS) of -4.41. The EPS increased by 3.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -204.4% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IMPL Forecast & Estimates
8 analysts have analysed IMPL and the average price target is 40.8 USD. This implies a price increase of 16822.44% is expected in the next year compared to the current price of 0.2411.
For the next year, analysts expect an EPS growth of 64.5% and a revenue growth 128.2% for IMPL